# MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06840665/  
OnCo record `nct06840665` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MR-guided adaptive radiotherapy in Rectal cancer, run by Fudan University, now recruiting.

## Summary

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT06840665 by Fudan University, with 46 participants planned, started 2024-08-13 and due to reach its primary completion in 2026-08-12. Interventions recorded: PD-1 antibody, Oxaliplatin, Capecitabine. Conditions recorded: Locally Advanced Rectal Cancer.

Linked to the technology MR-guided adaptive radiotherapy because the registry's title names it ("mr guided adaptive radiotherapy") and Rectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06840665
- Phase: 2
- Setting: A Prospective, Randomized, Phase II Trial of MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer
- Sponsor: Fudan University
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06840665: https://clinicaltrials.gov/study/NCT06840665

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [MR-guided adaptive radiotherapy](https://onco.cc/technologies/mr-linac/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06840665.json